{
  "symbol": "RGEN",
  "company": "Repligen Corporation",
  "generated_at": "2026-06-24T07:36:52.015Z",
  "event_count": 5,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-05T01:37:57.314Z",
      "stage": "analyst",
      "outcome": "skip",
      "reason": "Anti-signal gate triggered for convertible dilution (>10% of float). The 'accounting' flag refers to non-cash divestiture/restructuring charges, not irregularities, but the dilution overhang ($546M notes) combined with severely stretched valuation (49.7x Fwd P/E, 52x EV/EBITDA, <1% FCF yield) and zero insider buying makes this a skip. No margin of safety exists for equity or income structures.",
      "trigger": "watchlist rotation · core · frontier-2030s",
      "source": "watchlist"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-05T01:37:57.288Z",
      "skip": true,
      "reason": "Anti-signal gate triggered for convertible dilution (>10% of float). The 'accounting' flag refers to non-cash divestiture/restructuring charges, not irregularities, but the dilution overhang ($546M notes) combined with severely stretched valuation (49.7x Fwd P/E, 52x EV/EBITDA, <1% FCF yield) and zero insider buying makes this a skip. No margin of safety exists for equity or income structures.",
      "score": 16,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 2,
        "catalyst": 10,
        "mispricing": 0,
        "quality": 0,
        "technical": 4
      },
      "debug_path": "drafts/2026-06-05-RGEN.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-05T01:36:55.684Z",
      "summary": "Repligen is a life sciences bioprocessing tools company with ~$760M TTM revenue growing at ~15% organically. Q1 2026 delivered a +22.9% EPS surprise (beat by $0.09), with 50%+ analytics growth and strong China demand. The stock has been under severe pressure — down ~28% from its January 2026 high of $175.77 to current ~$126 — driven by multiple concerns: tariff uncertainty on biopharma equipment, customer concentration risk, and decelerating monoclonal antibody market growth. However, forward P/E of ~49.7x is expensive for a company with only 8.9% operating margin and 6.7% net margin, leaving limited upside without significant margin expansion. The CEO's tight vote (Karen Dawes/Carrie Eglinton Manner narrowly approved) and Glenn Muir's significant opposition (~25% against) signal governance tension. No open-market insider buys in the past 90 days — all recent Form 4s are equity compensation grants. The stock is below its 200-day MA, creating technical headwinds despite a recent MACD bullish cross.",
      "verdict": "range_bound_or_income",
      "confidence": 4,
      "tool_calls": 17,
      "walltime_min": 12,
      "debug_path": "dossiers/2026-06-05-RGEN.scout.debug.json"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-05-16T08:01:19.650Z",
      "skip": true,
      "reason": "Rich valuation (40x FPE, 42x EV/EBITDA) and broken technicals negate any income strategy edge. Material insider selling, convertible dilution overhang, and customer concentration trigger anti-signal gates, leaving no defensible entry point.",
      "score": 10,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 0,
        "catalyst": 5,
        "mispricing": 0,
        "quality": 5,
        "technical": 0
      },
      "debug_path": "drafts/2026-05-16-RGEN.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-16T08:00:43.470Z",
      "summary": "Repligen is a bioprocessing tools company (filtration, chromatography, analytics) that has been under significant pressure — down ~41% from its 52-week high of $175.77 and now near the low at $102.87. Q1 FY26 was a solid beat (+23% EPS surprise), full-year guidance raised to $1.97-$2.05 adjusted EPS, yet the stock has continued lower on broad sector rotation and valuation concerns. The forward P/E ~40x is rich vs. sector medians of 25-30x; EV/EBITDA ~42.5x is elevated for a tools name growing at mid-teens rates with 53% gross margins. Insiders are net sellers (CEO Loeillot sold ~$536K via pre-arranged 10b5-1 plan in April; director Muir exercised options and likely sold). No open-market purchase cluster exists. The stock sits well below both its 50-day ($118.81) and 200-day ($137.87) moving averages with RSI at 32.3 (oversold) but no reversal confirmation yet. IV is elevated (~52-62% ATM), making income strategies viable if the Analyst wants to play a range-bound bounce.",
      "verdict": "range_bound_or_income",
      "confidence": 4,
      "tool_calls": 21,
      "walltime_min": 19,
      "debug_path": "dossiers/2026-05-16-RGEN.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "RGEN",
    "call": "SELL",
    "confidence": 2,
    "score": -3,
    "factors": {
      "below_200dma": "-2",
      "above_50dma": "+1",
      "momentum_flat": "0 (-8.1%)",
      "rsi_neutral": "0 (52.2)",
      "recent_macd_bearish_cross": "-2 (0d ago)",
      "from_high": "0 (-26.6%)"
    },
    "summary": "SELL (score -3) · 12-1 mom -8.1% · RSI 52.2 · above_50_only · -26.6% from high",
    "last_close": 126.37,
    "one_month_ago_close": 113.37,
    "twelve_month_ago_close": 123.35,
    "twelve_one_momentum_pct": -8.09,
    "rsi_14": 52.2,
    "ma_stack": "above_50_only",
    "from_period_high_pct": -26.64,
    "period_high": 172.26,
    "price_targets": {
      "bear": 120.58,
      "fair": 141.39,
      "bull": 220,
      "bear_return_pct": -4.6,
      "fair_return_pct": 11.9,
      "bull_return_pct": 74.1,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 142,
        "target_mean": 176.10526,
        "target_high": 220,
        "analyst_count": 19
      }
    },
    "generated_at": "2026-06-24T07:36:52.011Z"
  }
}